Van ECK Associates Corp Has $3.07 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Van ECK Associates Corp lessened its holdings in Danaher Co. (NYSE:DHRGet Rating) by 66.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,874 shares of the conglomerate’s stock after selling 23,369 shares during the quarter. Van ECK Associates Corp’s holdings in Danaher were worth $3,067,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Advisor OS LLC increased its stake in shares of Danaher by 0.6% during the second quarter. Advisor OS LLC now owns 6,253 shares of the conglomerate’s stock valued at $1,585,000 after purchasing an additional 37 shares in the last quarter. American National Bank increased its stake in shares of Danaher by 31.9% during the third quarter. American National Bank now owns 157 shares of the conglomerate’s stock valued at $41,000 after purchasing an additional 38 shares in the last quarter. Strengthening Families & Communities LLC increased its stake in shares of Danaher by 3.2% during the second quarter. Strengthening Families & Communities LLC now owns 1,248 shares of the conglomerate’s stock valued at $364,000 after purchasing an additional 39 shares in the last quarter. Journey Advisory Group LLC increased its stake in shares of Danaher by 2.5% during the second quarter. Journey Advisory Group LLC now owns 1,648 shares of the conglomerate’s stock valued at $475,000 after purchasing an additional 40 shares in the last quarter. Finally, Rosenbaum Jay D. increased its stake in shares of Danaher by 1.1% during the second quarter. Rosenbaum Jay D. now owns 3,564 shares of the conglomerate’s stock valued at $904,000 after purchasing an additional 40 shares in the last quarter. Institutional investors and hedge funds own 77.26% of the company’s stock.

Danaher Trading Down 0.5 %

Shares of DHR stock opened at $272.31 on Friday. The firm’s 50 day moving average is $263.84 and its 200 day moving average is $267.93. The stock has a market capitalization of $198.23 billion, a P/E ratio of 30.09, a P/E/G ratio of 2.03 and a beta of 0.82. Danaher Co. has a 12-month low of $233.71 and a 12-month high of $306.37. The company has a current ratio of 1.78, a quick ratio of 1.38 and a debt-to-equity ratio of 0.41.

Danaher (NYSE:DHRGet Rating) last issued its quarterly earnings results on Thursday, October 20th. The conglomerate reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.24 by $0.32. The business had revenue of $7.66 billion for the quarter, compared to analysts’ expectations of $7.17 billion. Danaher had a net margin of 21.65% and a return on equity of 18.33%. The company’s revenue was up 6.0% compared to the same quarter last year. During the same quarter last year, the company posted $2.39 EPS. Research analysts expect that Danaher Co. will post 10.53 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 27th. Stockholders of record on Friday, December 30th will be paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 0.37%. The ex-dividend date of this dividend is Thursday, December 29th. Danaher’s dividend payout ratio is presently 11.05%.

Analysts Set New Price Targets

A number of brokerages have weighed in on DHR. Credit Suisse Group downgraded shares of Danaher from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $315.00 to $300.00 in a research note on Thursday, January 5th. Benchmark downgraded shares of Danaher from a “buy” rating to a “hold” rating and set a $325.00 price target for the company. in a research report on Monday, October 24th. Robert W. Baird reduced their price target on shares of Danaher from $325.00 to $315.00 and set an “outperform” rating for the company in a research report on Friday, October 21st. StockNews.com downgraded shares of Danaher from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 8th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Danaher from $350.00 to $315.00 and set an “overweight” rating for the company in a research report on Friday, October 21st. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $309.00.

Insider Transactions at Danaher

In other news, Director Alan G. Spoon sold 500 shares of Danaher stock in a transaction on Tuesday, October 25th. The shares were sold at an average price of $252.93, for a total transaction of $126,465.00. Following the transaction, the director now owns 107,135 shares in the company, valued at approximately $27,097,655.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, SVP Georgeann Couchara sold 1,884 shares of Danaher stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $271.61, for a total transaction of $511,713.24. Following the transaction, the senior vice president now owns 2,588 shares in the company, valued at approximately $702,926.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Alan G. Spoon sold 500 shares of Danaher stock in a transaction on Tuesday, October 25th. The shares were sold at an average price of $252.93, for a total transaction of $126,465.00. Following the transaction, the director now owns 107,135 shares in the company, valued at approximately $27,097,655.55. The disclosure for this sale can be found here. Insiders have sold 39,038 shares of company stock worth $10,550,749 in the last 90 days. 11.20% of the stock is currently owned by insiders.

Danaher Profile

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

Read More

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.